/IOBT
IOBT Stock - IO Biotech, Inc.
Healthcare|BiotechnologyNASDAQ
$0.66+6.83%
+$0.04 (+6.83%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+351.5%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IOBT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.66 – $0.67
TARGET (TP)$3.00
STOP LOSS$0.61
RISK/REWARD1:42.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.48
52W High$2.79
52W Low$0.32
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-849,000 | $-756,000 | $-540,000 | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-95,177,000 | $-91,443,000 | $-71,424,000 | $-41,234,000 | $-10,145,000 |
| Net Income | $-95,491,000 | $-86,083,000 | $-71,458,000 | $-67,879,000 | $-12,042,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.45 | $-1.98 | $-2.48 | $-2.36 | $-1.05 |
Company Overview
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
2
100%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish2 Neutral/Bearish
Price Targets
$0
Average Target
↓ 41.3% Downside
Now
$0
Low
$0
Average
$0
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 30th 2025 | TD Cowen | Downgrade | Hold | - |
| September 30th 2025 | Morgan Stanley | Downgrade | Equal Weight | $0.39 |
Earnings History & Surprises
IOBTBeat Rate
56%
Last 16 quarters
Avg Surprise
-136.7%
EPS vs Estimate
Beats / Misses
9/7
Last 12 quarters
Latest EPS
$-0.28
Q4 2025
EPS Surprise History
Q1 24
-11.1%
$-0.40vs$-0.36
Q2 24
+18.9%
$-0.30vs$-0.37
Q3 24
+8.8%
$-0.31vs$-0.34
Q4 24
-24.1%
$-0.36vs$-0.29
Q1 25
-25.2%
$-0.48vs$-0.38
Q2 25
+24.4%
$-0.34vs$-0.45
Q3 25
-14.3%
$-0.40vs$-0.35
Q4 25
+9.7%
$-0.28vs$-0.31
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.16 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.35 | $-0.40 | -14.3% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.45 | $-0.34 | +24.4% | ✓ BEAT |
Q1 2025 | Mar 25, 2025 | $-0.38 | $-0.48 | -25.2% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.29 | $-0.36 | -24.1% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.34 | $-0.31 | +8.8% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.37 | $-0.30 | +18.9% | ✓ BEAT |
Q1 2024 | Mar 5, 2024 | $-0.36 | $-0.40 | -11.1% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.47 | $-0.43 | +8.5% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-0.66 | $-0.74 | -12.1% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.72 | $-0.59 | +18.1% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $-0.57 | $-0.69 | -21.1% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.73 | $-0.56 | +23.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.65 | $-0.64 | +1.5% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.69 | $-0.60 | +13.0% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-0.83 | — | — |
Q4 2021 | Dec 17, 2021 | $-1.60 | $-36.88 | -2205.0% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | — | $-3.32 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.32 | — | — |
Latest News
IO Biotech Announces Publication In Nature Communications Of Long-Term Clinical And Immunological Outcomes From Phase 1/2 Trial MM1636
📈 PositiveBenzinga•Dec 15, 2025, 09:08 PM
IO Biotech Q3 EPS $(0.13) Beats $(0.34) Estimate
📈 PositiveBenzinga•Nov 14, 2025, 01:11 PM
IO Biotech To Present New Pre-Clinical Data For Next Vaccine Candidate, IO112, And Additional Candidate, IO170, At SITC 2025
📈 PositiveBenzinga•Nov 7, 2025, 02:06 PM
Piper Sandler Maintains Overweight on IO Biotech, Lowers Price Target to $3
➖ NeutralBenzinga•Oct 22, 2025, 03:26 PM
IO Biotech shares are trading higher after the company announced results from its global Phase 3 trial of Cylembio, in combination with Merck's anti-PD-1 therapy KEYTRUDA, for the first-line treatment of patients with unresectable or metastatic melanoma.
📈 PositiveBenzinga•Oct 20, 2025, 01:11 PM•Also:
IO Biotech Phase 3: Cylembio Plus KEYTRUDA Extends Median PFS To 19.4 Months In First-Line Advanced Melanoma, Showing Clinically Meaningful Improvement Despite Narrow Miss On Statistical Significance
📈 PositiveBenzinga•Oct 20, 2025, 06:48 AM
TD Cowen Downgrades IO Biotech to Hold
📉 NegativeBenzinga•Sep 30, 2025, 03:15 PM
HC Wainwright & Co. Downgrades IO Biotech to Neutral
➖ NeutralBenzinga•Sep 29, 2025, 04:24 PM
IO Biotech shares are trading lower after the FDA recommended the company not submit a BLA based on data from its IOB-013 trial.
📉 NegativeBenzinga•Sep 29, 2025, 04:07 PM
IO Biotech Plans To Design New Registrational Study For Cylembio For Treatment Of First-Line Patients With Advanced Melanoma; Implements Restructuring, Reducing Workforce By ~50%
📉 NegativeBenzinga•Sep 29, 2025, 11:16 AM
IO Biotech Issues Update On Regulatory Pathway For Cylembio Following Pre-BLA Meeting With FDA; FDA Recommends That IO Biotech Not Submit BLA Based On Data From IOB-013 Clinical Trial
📉 NegativeBenzinga•Sep 29, 2025, 11:15 AM
IO Biotech To Present Phase 3 And Final Phase 2 Trial Results For IO102-IO103 Cancer Vaccine Plus Pembrolizumab At 2025 ESMO Congress
➖ NeutralBenzinga•Sep 23, 2025, 12:06 PM
Io Biotech Posts Wider Loss in Q2
📉 NegativeThe Motley Fool•Aug 14, 2025, 10:07 PM
IO Biotech says cancer vaccine with Merck's Keytruda outperformed in late-stage study
📈 PositiveSeeking Alpha•Aug 11, 2025, 12:29 PM•Also:
Frequently Asked Questions about IOBT
What is IOBT's current stock price?
IO Biotech, Inc. (IOBT) is currently trading at $0.66 per share. The stock has moved +6.83% today.
What is the analyst price target for IOBT?
The average analyst price target for IOBT is $3.00, based on 1 analyst.
What sector is IO Biotech, Inc. in?
IO Biotech, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IOBT's market cap?
IO Biotech, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does IOBT pay dividends?
No, IO Biotech, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACET
Adicet Bio, Inc.
$0.49
Mkt Cap: $0.0B
CUE
Cue Biopharma, Inc.
$0.27
Mkt Cap: $0.0B
HOWL
Werewolf Therapeutics, Inc.
$0.69
Mkt Cap: $0.0B
INKT
MiNK Therapeutics, Inc.
$11.59
Mkt Cap: $0.1B
KPTI
Karyopharm Therapeutics Inc.
$6.94
Mkt Cap: $0.1B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
OSTX
OS Therapies Incorporated
$1.54
Mkt Cap: $0.1B
OTLK
Outlook Therapeutics, Inc.
$2.01
Mkt Cap: $0.1B
SPRB
Spruce Biosciences, Inc.
$78.74
Mkt Cap: $0.0B
Explore stocks similar to IOBT for comparison